

Lung Cancer™

U P D A T E

An Audio Review Journal for Nurses

EDITOR

Neil Love, MD

INTERVIEWS

Alan B Sandler, MD

Ann Culkin, RN, OCN

Beth Eaby, MSN, CRNP, OCN

Leslie Tyson, MS, APRN-BC, OCN

Jeanne Griffin, NP



STATEMENT OF NEED/TARGET AUDIENCE

Lung cancer is the leading cause of cancer mortality in the United States in both men and women. Chemotherapy, surgery and radiation therapy have had a modest effect on patient outcomes. However, recent improvements have been seen in time to progression and survival in lung cancer clinical trials. Research findings and ongoing clinical trials lead to the continuous emergence of new drugs and therapies and changes in the indications for existing treatments. To offer their patients the best care possible, oncology nurses need to be aware of ongoing research and changes in cancer care so as to include the widening array of therapeutic options for cancer patients in their everyday disease management decisions. To assist with meeting this need, *Lung Cancer Update for Nurses* provides an overview of the latest research developments in lung cancer and the opinions of oncology nurses, patients and clinical investigators with experience and expertise in the field.

PURPOSE STATEMENT

To present the most current research developments in lung cancer and to provide the perspectives of medical oncologists and oncology nurses on the diagnosis and treatment of lung cancer.

EDUCATIONAL OBJECTIVES FOR THIS ISSUE OF *LUNG CANCER UPDATE FOR NURSES*

- Describe the types and stages of lung cancer and the stage-based modalities utilized in the disease.
- Discuss nursing management of disease-related symptoms and treatment side effects.
- Describe the risks and benefits of chemotherapeutic agents and regimens in the adjuvant, locally advanced and metastatic settings.
- Explain the risks and benefits of incorporating biologic agents in the adjuvant, locally advanced and metastatic settings.
- Discuss key clinical trials in lung cancer in the adjuvant, locally advanced and metastatic settings.
- Discuss psychosocial and emotional needs of caregivers, patients and their loved ones associated with the diagnosis and treatment of lung cancer.

ACCREDITATION STATEMENTS

This educational activity for 3.1 contact hours is provided by Research To Practice during the period of July 2007 through July 2008.

Research To Practice is an approved provider of continuing nursing education by the New Jersey State Nurses Association, Provider Number P215-01/07-10. NJSNA is accredited by the ANCC Commission on Accreditation. Provider Approval is valid through January 31, 2010.

HOW TO USE THIS CNE ACTIVITY

This is an audio CNE program. This book contains CNE information, including learning objectives, faculty disclosures, a Post-test and an Evaluation Form. The corresponding website LungCancerUpdate.com/Nurses also includes links to relevant abstracts and full-text articles.

The Post-test and Evaluation Form may be completed in this book and either mailed to Research To Practice, 2 South Biscayne Blvd, Suite 3600, Miami, FL 33131 or faxed to (800) 447-4310. They may also be completed online. A statement of credit will be issued only upon receipt of a completed Post-test with a score of 70 percent or better and a completed Evaluation Form. Your statement of credit will be mailed to you within three weeks or may be printed online.

This program is supported by education grants from Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Genentech BioOncology/OSI Pharmaceuticals Inc and Sanofi-Aventis.

If you would like to discontinue your complimentary subscription to *Lung Cancer Update for Nurses*, please email us at Info@ResearchToPractice.com, call us at (800) 648-8654 or fax us at (305) 377-9998. Please include your full name and address, and we will remove you from the mailing list.

Lung Cancer™

U P D A T E

EDITOR



Neil Love, MD

Medical Oncologist
Editor, *Lung Cancer Update* for Nurses
Research To Practice
Miami, Florida



Beth Eaby, MSN, CRNP, OCN

Outpatient Thoracic Oncology
Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

FACULTY AFFILIATIONS



Alan B Sandler, MD

Associate Professor of Medicine
Medical Director, Thoracic Oncology
Director, Vanderbilt-Ingram Cancer
Center Affiliate Network Program
Vanderbilt University Medical Center
Division of Hematology/Oncology
Nashville, Tennessee



Leslie Tyson, MS, APRN-BC, OCN

Nurse Practitioner
Thoracic Oncology Service
Memorial Sloan-Kettering
Cancer Center
New York, New York



Ann Culkin, RN, OCN

Thoracic Oncology Service
Ambulatory Nursing
Memorial Sloan-Kettering
Cancer Center
New York, New York



Jeanne Griffin, NP

Nurse Practitioner
Massachusetts General Hospital
Cancer Center
Boston, Massachusetts

CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest for themselves (or their spouses/partners) that have been resolved through a peer review process: Lisa Aiello-Laws, RN, MSN, APN-C, AOCNS, John Brebner, Regina Seery Cunningham, PhD, RN, AOCN, Richard Kaderman, PhD, Joanne Librie, RN, Neil Love, MD, Douglas Paley, Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Ginelle Suarez, Erin Wall and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Aviva Asnis-Alibozek, PA-C, MPAS — salary: AstraZeneca Pharmaceuticals LP; shareholder of AstraZeneca Pharmaceuticals LP; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc and Genentech BioOncology. Research To Practice receives education grants from Abraxis BioScience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Genentech BioOncology/OSI Pharmaceuticals Inc, Genomic Health Inc, GPC Biotech, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.

In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:

Dr Sandler — Contracted Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology, OSI Pharmaceuticals Inc, Pfizer Inc, Sanofi-Aventis; Consulting Fees: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb Company, Cyclacel Pharmaceuticals Inc, Eli Lilly and Company, Genentech BioOncology, OSI Pharmaceuticals Inc, Pfizer Inc, Sanofi-Aventis, Wyeth; Speakers Bureau: Genentech BioOncology. **Ms Culkin** — Consulting Fees: Genentech BioOncology, OSI Pharmaceuticals Inc, Roche Laboratories Inc; Speakers Bureau: Eli Lilly and Company, NMCR Analytics. **Ms Eaby** — Speakers Bureau: Amgen Inc, Genentech BioOncology, Merck and Company Inc, Sanofi-Aventis. **Ms Tyson** — No financial interests or affiliations to disclose. **Ms Griffin** — No financial interests or affiliations to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

QUESTIONS (PLEASE CIRCLE ANSWER):

1. **Non-small cell lung cancer (NSCLC) is staged according to _____.**
 - a. Tumor size
 - b. Nodal status
 - c. Evidence of metastasis
 - d. All of the above
2. **When contemplating adjuvant chemotherapy for a patient with NSCLC, which of the following factors should be considered?**
 - a. Postoperative performance status
 - b. Stage
 - c. Comorbidities
 - d. All of the above
3. **Eaby and colleagues suggest that the grading of dermatologic reactions secondary to epidermal growth factor receptor inhibitors and resulting alterations in treatment should be based on _____.**
 - a. Body surface area involved
 - b. Severity of symptoms and impact on daily activities
4. **In the trial ECOG-E4599, evaluating paclitaxel/carboplatin with or without bevacizumab in metastatic disease, which regimen demonstrated a survival advantage?**
 - a. Paclitaxel/carboplatin
 - b. Paclitaxel/carboplatin/bevacizumab
5. **ECOG-1505 will evaluate the use of three cisplatin-based regimens with or without _____ as adjuvant therapy for NSCLC.**
 - a. Erlotinib
 - b. Bevacizumab
 - c. Nab paclitaxel
6. **Bevacizumab-related side effects include all of the following except _____.**
 - a. Proteinuria
 - b. Hypertension
 - c. Hemoptysis
 - d. Alopecia areata
7. **Due to the risk of pulmonary hemorrhage, bevacizumab should not be administered to patients with _____.**
 - a. Controlled hypertension
 - b. Gross hemoptysis
 - c. Squamous cell histology
 - d. Both b and c
8. **Which of the following is an advantage associated with nab paclitaxel?**
 - a. No need to administer premedication
 - b. Shorter infusion time
 - c. Both a and b
9. **In early trials, patients who were most responsive to tyrosine kinase inhibitors included _____.**
 - a. Women
 - b. Patients who had never smoked
 - c. Patients with adenocarcinomas
 - d. All of the above
10. **Nursing recommendations to reduce side effects of erlotinib include all of the following except _____.**
 - a. Moisturize dry areas with an emollient-type cream
 - b. Take erlotinib on an empty stomach
 - c. Limit exposure to sunlight
 - d. Take systemic antibiotics as preventive therapy

EVALUATION FORM

Lung Cancer Update for Nurses — Issue 1, 2007

Research To Practice respects and appreciates your opinions. To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please take a few minutes to complete this Evaluation Form. A statement of credit will be issued only upon receipt of a completed Evaluation Form and a completed Post-test with a score of 70 percent or better.

Please answer the following questions by circling the appropriate rating:

5 = Outstanding 4 = Good 3 = Satisfactory 2 = Fair 1 = Poor

EXTENT TO WHICH PROGRAM ACTIVITIES MET THE IDENTIFIED GOAL

- To present the most current research developments in lung cancer and to provide the perspectives of medical oncologists and oncology nurses on the diagnosis and treatment of lung cancer.....5 4 3 2 1

EXTENT TO WHICH PROGRAM ACTIVITIES MET THE IDENTIFIED OBJECTIVES

Upon completion of this activity, participants should be better able to:

- Describe the types and stages of lung cancer and the stage-based modalities utilized in the disease.....5 4 3 2 1
- Discuss nursing management of disease-related symptoms and treatment side effects.....5 4 3 2 1
- Describe the risks and benefits of chemotherapeutic agents and regimens in the adjuvant, locally advanced and metastatic settings.5 4 3 2 1
- Explain the risks and benefits of incorporating biologic agents in the adjuvant, locally advanced and metastatic settings.5 4 3 2 1
- Discuss key clinical trials in lung cancer in the adjuvant, locally advanced and metastatic settings..5 4 3 2 1
- Discuss psychosocial and emotional needs of caregivers, patients and their loved ones associated with the diagnosis and treatment of lung cancer.....5 4 3 2 1

EFFECTIVENESS OF THE INDIVIDUAL FACULTY MEMBERS

Faculty	Knowledge of subject matter	Effectiveness as an educator
Alan B Sandler, MD	5 4 3 2 1	5 4 3 2 1
Ann Culkin, RN, OCN	5 4 3 2 1	5 4 3 2 1
Beth Eaby, MSN, CRNP, OCN	5 4 3 2 1	5 4 3 2 1
Leslie Tyson, MS, APRN-BC, OCN	5 4 3 2 1	5 4 3 2 1
Jeanne Griffin, NP	5 4 3 2 1	5 4 3 2 1

OVERALL EFFECTIVENESS OF THE ACTIVITY

- Will assist me in improving patient care. 5 4 3 2 1
- Fulfilled my educational needs. 5 4 3 2 1
- Avoided commercial bias or influence. 5 4 3 2 1

IMPACT OF THE ACTIVITY

The information presented (check all that apply):

- Reinforced my current practice/treatment habits. Enhanced my current knowledge base.

EVALUATION FORM

Lung Cancer Update for Nurses — Issue 1, 2007

IMPACT OF THE ACTIVITY (CONTINUED)

Will the information presented cause you to make any changes in your practice?

- Yes No

If yes, please describe any change(s) you plan to make in your practice as a result of this activity:

.....
.....

How committed are you to making these changes?

(5 = very committed; 1 = not at all committed).....5 4 3 2 1

FUTURE ACTIVITIES

Do you feel future activities on this subject matter are necessary and/or important to your practice?

- Yes No

Please list any other topics that would be of interest to you for future educational activities:

.....
.....

Additional comments about this activity:

.....
.....

FOLLOW-UP

As part of our ongoing, continuous quality-improvement effort, we conduct postactivity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey:

- Yes, I am willing to participate in a follow-up survey. No, I am not willing to participate in a follow-up survey.

REQUEST FOR CREDIT — please print clearly

Name: Degree:

Organization: Specialty:

Address:

City, State, Zip:

Telephone: Fax: Email:

Signature: Date:

Which of the following audio formats of this program did you use?

- Audio CDs Downloaded MP3s from website

To obtain credit, complete the Post-test and Evaluation Form and either mail to Research To Practice, 2 South Biscayne Blvd, Suite 3600, Miami, FL 33131, fax to (800) 447-4310 or complete both online. A statement of credit will be issued only upon receipt of a completed Post-test with a score of 70 percent or better and a completed Evaluation Form. Your statement of credit will be mailed to you within three weeks or may be printed online.

Lung Cancer™

U P D A T E

Editor/CME Director	Neil Love, MD
Managing Editor	Kathryn Ault Ziel, PhD
Scientific Director	Richard Kaderman, PhD
Senior Director, Medical Affairs	Aviva Asnis-Alibozek, PA-C, MPAS
Writers	Lillian Sklaver Poltorack, PharmD Douglas Paley
Continuing Education Administrator for Nursing	Sally Bogert, RNC, WHCNP
Content Validation	Margaret Peng John Brebner Ginelle Suarez Erin Wall
Director, Creative and Copy Editing	Aura Herrmann
Creative Manager	Fernando Rendina
Graphic Designers	Jason Cunnius Tamara Dabney Shantia Daniel Elisa Stambouli
Senior Production Editor	Alexis Oneca
Traffic Manager	Tere Sosa
Copy Editors	Dave Amber Margo Harris Rosemary Hulce Kirsten Miller Pat Morrissey/Havlin Carol Peschke Susan Petrone
Production Manager	Rena Chiarelli
Audio Production	Frank Cesarano
Web Master	John Ribeiro
Contact Information	Neil Love, MD Research To Practice One Biscayne Tower 2 South Biscayne Boulevard, Suite 3600 Miami, FL 33131 Fax: (305) 377-9998 Email: NLove@ResearchToPractice.com
For CNE Information	Email: CNE@ResearchToPractice.com

Copyright © 2007 Research To Practice. All rights reserved.

The compact discs, Internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their

own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.

Lung Cancer™

U P D A T E

Copyright © 2007 Research To Practice.

This program is supported by education grants from
Abraxis BioScience, AstraZeneca Pharmaceuticals LP,
Genentech BioOncology/OSI Pharmaceuticals Inc and Sanofi-Aventis.



Sponsored by Research To Practice.

Last review date: July 2007

Release date: July 2007

Expiration date: July 2008

Contact hours: 3.1